Products are for professional/laboratory use only.
Cell Marque™ Tissue Diagnostics SDHB (EP288) is now available. Succinate dehydrogenase B (SDHB) is a useful antibody for subtyping Gastrointestinal stromal tumours (GIST).
Gastrointestinal stromal tumours (GIST) are the most prevalent mesenchymal tumours of the digestive tract.2 It is believed that these tumours arise from the interstitial cells of Cajal which can mediate peristalsis through the autonomic nervous system. GISTs can be found in people of all ages but are most prevalent in middle-aged people.1
The majority of gastrointestinal tumours are associated with KIT or PDGFRA mutations3 and the remaining 15% of GISTs are considered “wild-type” since they don’t have either mutation. This group is normally identified using IHC with the DOG1 antibody. Within the wild-type GISTs are succinate dehydrogenase-deficient GISTs which are mostly located in the stomach of younger patients.3
Differentiating GIST from such mimics as leiomyoma, fibromatosis or solitary fibrous tumour can be accomplished with the use of the following antibodies: CD34, DOG1, STAT6, beta-catenin and transgelin. Antibodies useful in subtyping GIST include those targeting CD34, zcd117, DOG1 and succinate dehydrogenase B (SDHB).
Benefits of SDHB (EP288) include:
-
For in vitro diagnostic use
-
Differentiates SDHB-mutated wild-type GIST from other GIST subtypes
- High sensitivity and specificity for SDHB-mutated wild-type GISTs
The Cell Marque SDHB antibody is available in the following formats:
|
Volume |
Product Code |
|
0.1ml concentrate |
CM466R14 |
|
0.5ml concentrate |
CM466R15 |
|
1.0ml concentrate |
CM466R16 |
|
1.0ml predilute |
CM466R17 |
|
7.0ml predilute |
CM466R18 |
References:
1. https://www.mayoclinic.org/diseases-conditions/gastrointestinal-stromal-tumors/cdc-20387715
2. Ya-Mei Wang, et al. World J Gastroenterol. 2015; 21(8):2303–2314
3. Miettinen M, et al. Am J Surg Pathol. 2011; 35(11):1712-21
